Status:
ACTIVE_NOT_RECRUITING
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
Lead Sponsor:
AdventHealth Translational Research Institute
Conditions:
Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Brief Summary
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that ...
Eligibility Criteria
Inclusion
- Preoperative MRI consistent with a primary intracranial malignant brain tumor.
- Must be 18 years of age or older.
- Patient eligible for debulking surgery/resection.
Exclusion
- Inability to obtain pre-operative IV access.
- Use of Tru Niagen, Basis (or any other nicotinamide riboside (NR)-containing NAD+ booster) or niacin supplements within one month prior to Study Visit 1.
- Participation in studies involving investigational drug(s) within 30 days prior to Study Visit 1
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Study Visit 1 (participants may not donate blood any time during the study, through the final study day)
- Presence of any condition that, in the opinion of Dr. Field, compromises participant safety or data integrity or the participant's ability to complete study days.
- Pregnancy, lactation or \< 9 months postpartum from the Study Visit 1 date.
Key Trial Info
Start Date :
September 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT06054529
Start Date
September 11 2023
End Date
December 1 2025
Last Update
March 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AdventHealth Translational Research Institute
Orlando, Florida, United States, 32804